Meeting Banner
Abstract #1033

13C Hyperpolarized Anticoagulants

Joachim Bargon1, Johannes Bernarding2, Rahim Rizi3, Hans-Wolfgang Spiess4, Kerstin Mnnemann4, Meike Roth4, Ute Bommerich5

1Institute of Physical and Theoretical Chemistry, University of Bonn, Bonn, NRW, Germany; 2Institute of Biometry, University of Magdeburg, Magdeburg, Germany; 3Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States; 4NMR, Max-Planck Institute of Polymers, Mainz, Germany; 5Institute of Neurobiology, Magdeburg, Germany

Anticoagulants like warfarin, phenprocoumon, and pentoxifylline are used to alleviate the disabling consequences of strokes, the leading cause of disability in the US and third leading cause of death. Similarly, the phosphodiesterase inhibitor pentoxifylline inhibits multiple processes including inflammation, coagulation, and edema that lead to neonatal hyperoxic lung injury, whereby. bronchopulmonary dysplasia is a leading cause of mortality and morbidity in preterm infants despite improved treatment. All of these anticoagulants can be 13C-hyperpolarized for 13C-MRI/MRS-studies upon parahydrogenation of suitably unsaturated precursors, preferably at low magnetic fields. Differing from DNP, this procedure can provide a steady flow of 13C-hyperpolarized drugs.